HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
